Hosted on MSN15d
Eli Lilly pays $10m upfront for Organovo’s FXR agonist
In addition, Eli Lilly announced earlier this month that it is paying $630m for South Korea-based biotech OliX Pharmaceuticals’ antisense RNAi oligonucleotide OLX75016 to treat MASH. "Eli Lilly pays ...
Hosted on MSN1mon
Eli Lilly pledges $630m on OliX’s Phase I RNA candidate for MASH
Eli Lilly is paying up to $630m for a Phase I metabolic-associated steatohepatitis (MASH) candidate from South Korea-based biotech OliX Pharmaceuticals, diversifying its pipeline for the disease ...